Antoine Italiano
Institut Bergonié · Institut Bergonie, Bordeaux, France · Gustave Roussy, Cancer Campus, Grand Paris
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Antoine Italiano as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:05 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06084689 · Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid StructuresInstitut Bergonié · withdrawn · Adult Soft Tissue Sarcoma, Non Small Cell Lung Cancer, Triple Negative Breast Cancer · principal investigator
- Ph1/Ph2NCT05920408 · Study to Assess EXS21546 in Combination in Patients With Advanced Solid TumoursExscientia AI Limited · terminated · Advanced Solid Tumours · principal investigator
- N/ANCT04932525 · Gustave Roussy Cancer ProfilingGustave Roussy, Cancer Campus, Grand Paris · recruiting · Solid Tumor, Unspecified, Adult · principal investigator
- N/ANCT04010240 · A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK StudyInstitut Bergonié · completed · Metastatic Solid Tumors · principal investigator
- N/ANCT03977818 · Patterns of Care and Outcomes in METAstatic Soft Tissue SARComaInstitut Bergonié · completed · Sarcoma, Metastases, Chemotherapy · principal investigator
- Ph3NCT03784014 · Molecular Profiling of Advanced Soft-tissue SarcomasInstitut National de la Santé Et de la Recherche Médicale, France · completed · Soft Tissue Sarcoma · principal investigator
- N/ANCT03676270 · Trends in Modern Phase 1 Oncology TrialsInstitut Bergonié · completed · Cancer · principal investigator
- Ph1/Ph2NCT02630368 · A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)Institut Bergonié · unknown · Solid Tumors, Soft-tissue Sarcoma, Breast Cancer · study chair
- N/ANCT02534649 · Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase TrialsInstitut Bergonié · recruiting · Solid Tumor, Hematological Malignancy · study chair
- Ph2NCT02406781 · Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II TrialInstitut Bergonié · completed · Sarcoma · study chair
- Ph2NCT02243605 · Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing SarcomaNational Cancer Institute (NCI) · active not recruiting · Metastatic Ewing Sarcoma, Metastatic Osteosarcoma, Recurrent Ewing Sarcoma · principal investigator
- Ph2NCT01907607 · Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and SunitinibInstitut Bergonié · completed · Advanced Gastrointestinal Stromal Tumors · principal investigator
- Ph2NCT01876043 · Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter TrialInstitut Bergonié · terminated · Adult Patients With Unresectable Locally Advanced or Metastatic, Relapsed/Refractory Dedifferentiated Liposarcoma · study chair
- Ph2NCT01267955 · Vismodegib in Treating Patients With Advanced ChondrosarcomasNational Cancer Institute (NCI) · active not recruiting · Clear Cell Chondrosarcoma, Dedifferentiated Chondrosarcoma, Locally Advanced Chondrosarcoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:05 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:05 UTC. The ranking covers the 200 most relevant of 156 PubMed records, and a shared surname and initials can bring in a namesake. All 156 on PubMed
- 2,186 citationsRCR 94.0
- Sotorasib for Lung Cancers with KRAS p.G12C Mutation.N Engl J Med · 20211,561 citationsRCR 84.2
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.N Engl J Med · 20151,444 citationsRCR 41.8
- Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study.J Clin Oncol · 2019885 citationsRCR 34.7
- 591 citationsRCR 21.6
- Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.Lancet Oncol · 2018530 citationsRCR 16.4
- Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.J Clin Oncol · 2022428 citationsRCR 28.3
- Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.Lancet Oncol · 2020426 citationsRCR 15.2
- Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.Lancet Oncol · 2020423 citationsRCR 17.3
- Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial.JAMA Oncol · 2018365 citationsRCR 12.0